**Table S2. Cell viability assay for treatment of candidate compounds from HTS.**

|  |  |
| --- | --- |
|  | **Cell Viability (%)** |
| ***Concentration (microM)*** | ***7.1*** | ***14.3*** | ***28.6*** | ***57.1*** | ***114.2*** |
| ***Cell Lines*** | ***CTRL*** | ***MLD*** | ***CTRL*** | ***MLD*** | ***CTRL*** | ***MLD*** | ***CTRL*** | ***MLD*** | ***CTRL*** | ***MLD*** |
| ***Small Molecules from LOPAC\**** |
| ***JFD00244*** | 61.1 | 75 | 27 | 9.5 | 28.1 | 19.5 | 2.9 | 1 | 3.7 | 0.8 |
| ***6-OH-DL-Dopa*** | 112 | 100 | 102.6 | 103.2 | 107.2 | 95.2 | 99.4 | 92.1 | 109.3 | 109.6 |
| ***Methoxyverapamil HCl*** | 78.8 | 102.5 | 76.2 | 105.3 | 73.2 | 96 | 76.8 | 84.6 | 83.7 | 78.1 |
| ***DL-E-Dihydrosphingosine*** | 69 | 97.7 | 25.9 | 76 | 0.5 | 0.6 | 0.9 | 0.6 | 0.5 | 0.7 |
| ***6-OH-melatonin*** | 90.1 | 84.7 | 90.7 | 78.4 | 80.7 | 75 | 89.6 | 95 | 88.4 | 88.6 |
| ***Tyrphostin AG 536*** | 79.6 | 102.3 | 88.3 | 97.5 | 69.2 | 92.6 | 58.3 | 91.7 | 79.5 | 74.6 |

\*LOPAC, Library of Pharmacological Active Compounds.